Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2018 Aug 30:9:728.
doi: 10.3389/fneur.2018.00728. eCollection 2018.

Reversible Valproate-Induced Subacute Encephalopathy Associated With a MT-ATP8 Variant in the Mitochondrial Genome

Affiliations
Case Reports

Reversible Valproate-Induced Subacute Encephalopathy Associated With a MT-ATP8 Variant in the Mitochondrial Genome

Giovanna De Michele et al. Front Neurol. .

Abstract

Introduction: There are several reported cases of patients developing motor and cognitive neurological impairment under treatment with valproic acid (VPA). We describe a woman who developed a subacute encephalopathy after VPA intake, harboring a mitochondrial DNA variant, previously described as causing VPA sensitivity in one pediatric patient. Material and Methods: A 65-year old woman developed a progressive, severe neurological deterioration after a 3 month treatment with valproate sodium, 800 mg daily. Magnetic resonance spectroscopy (MRS), muscle histochemical analysis and assay of mitochondrial enzymatic activities, and mitochondrial DNA sequencing were performed. Results: Neurological examination showed drowsiness, vertical gaze palsy, inability to either stand or walk, diffuse weakness, increased tendon reflexes. Blood lactate was increased, EEG showed diffuse theta and delta activity, MRI subcortical atrophy and leukoencephalopathy, MRS marked reduction of the NAA spectrum, with a small signal compatible with presence of lactate. Muscle biopsy evidenced presence of ragged red fibers (20%) and reduced COX reactivity. Assay of the muscle enzymatic activities showed multiple deficiencies of the electron transport chain and reduced ATP production. The mt.8393C>T variant in the MT-ATP8 gene was found in homoplasmy. The patient considerably improved after valproate withdrawal. Conclusion: The variant we found has been reported both as a polymorphism and, in a single patient, as related to the valproate-induced encephalopathy. The present case is the first bearing this mutation in homoplasmy. In case of neurological symptoms after starting VPA therapy, once hyperammonemia and liver failure have been ruled out, mtDNA abnormalities should be considered.

Keywords: MT-ATP8; ammonia; metabolic encephalopathy; mitochondria; valproate.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Pedigree of the family. Circles are women and squares are men. A shaded symbol indicates the proposita, half-shaded symbols indicate asymptomatic carriers of the homoplasmic m.8393C>T/p.Pro10Ser variant in MT-ATP8.
Figure 2
Figure 2
(A) EEG showing a slow alpha with theta and delta activity (blue arrow); (B,C) MRI scan showing cortical and subcortical atrophy with confluent areas of white matter hyperintensity (red arrows) in T1 and T2-weighted images.
Figure 3
Figure 3
Hematoxylin and eosin stain (A) and Gömöri trichrome stain (B, 20X) showed variability of muscle morphology with some atrophic fibers. In (B) asterisks denote some ragged-red fibers. Double cytochrome c-oxidase/succinate dehydrogenase (COX/SDH) stain (40X) is depicted in panel (C); a single COX-deficient blue fiber is indicated (arrow). In (D) SDH staining (10X) showed globally reduced activity.

References

    1. Galimberti CA, Diegoli M, Sartori I, Uggetti C, Brega A, Tartara A, et al. Brain pseudo-atrophy and mental regression on valproate and a mitochondrial DNA mutation. Neurology (2006) 67:1715–7. 10.1212/01.wnl.0000242882.58086.9a - DOI - PubMed
    1. Nesti C, Meschini MC, Meunier B, Sacchini M, Doccini S, Romano A, et al. . Additive effect of nuclear and mitochondrial mutations in a patient with mitochondrial encephalomyopathy. Hum Mol Genet. (2015) 24:3248–56. 10.1093/hmg/ddv078 - DOI - PubMed
    1. Tomson T, Battino D, Perucca E. Valproic acid after five decades of use in epilepsy: time to reconsider the indications of a time-honoured drug. Lancet Neurol. (2016) 15:210–8. 10.1016/S1474-4422(15)00314-2 - DOI - PubMed
    1. Verrotti A, Trotta D, Morgese G, Chiarelli F. Valproate-induced hyperammonemic encephalopathy. Metab Brain Dis. (2002) 17:367–73. 10.1023/A:1021918104127 - DOI - PubMed
    1. Gerstner T, Buesing D, Longin E, Bendl C, Wenzel D, Scheid B, et al. Valproic acid induced encephalopathy−19 new cases in Germany from 1994 to 2003–a side effect associated to VPA-therapy not only in young children. Seizure (2006) 15:443–8. 10.1016/j.seizure.2006.05.007 - DOI - PubMed

Publication types

LinkOut - more resources